Former Crick COO outlines to do list for U.K. antibiotics initiative to succeed

For the U.K.’s newly unveiled subscription model to succeed in re-invigorating antimicrobial investment, David Roblin believes at least a $10 million annual payment to participating companies from the country will be sufficient.

Additionally, "you need to get a subscription model with several hundred millions worldwide annually for one product" while building flexibility into the model to balance the volume of use of new antibiotics, said Roblin, who is COO and CMO of antibiotics company Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) and former COO and director of scientific translation at London’s Francis Crick Institute...